enGene Therapeutics Inc. reported financial results for the third quarter ended July 31, 2026, posting a net loss of $32.5 million, or $0.47 per share, compared to $29.0 million in the prior year period. Total operating expenses rose to $34.0 million from $29.9 million, driven by increased general and administrative costs related to workforce reductions and personnel annualization, partially offset by lower research and development spending. The company ended the quarter with $266.3 million in cash, cash equivalents, and marketable securities. Clinically, enGene cleared a safety run-in for a surfactant plus detalimogene cohort and plans to report updated regulatory endpoint data from its pivotal LEGEND trial in the fourth quarter of 2026. The company also anticipates initiating a Biologics License Application (BLA) submission before year-end and holding a pre-BLA meeting with the FDA during that period. enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines for mucosal tissues, specifically targeting non-muscle invasive bladder cancer.

Dr. Richard Glickman resigned as Chairman of the Board of Directors, effective July 15, 2026. Michael Heffernan, a current Board member, has been appointed as the new Chairman of the Board. enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines.

enGene Therapeutics Inc. amended its previous 8-K to update restructuring costs following a 50% workforce reduction. The company approved performance-based equity retention awards for employees, including CEO Ronald Cooper, which vest upon FDA BLA filing acceptance and detalimogene regulatory approval by late 2027 and 2028 respectively. Total estimated restructuring costs include $5.7 to $6.4 million in cash and up to $4.7 to $5.0 million in non-cash stock-based compensation. enGene Therapeutics Inc. is a biotechnology company developing gene therapies.

enGene Therapeutics Inc. announced a strategic restructuring plan effective June 14, 2026, involving a workforce reduction of approximately 50% to preserve cash and streamline operations. The company expects to incur restructuring costs between $5.7 million and $6.4 million, plus $4.7 million to $5.0 million in non-cash stock-based compensation. Several key executives are departing, including Chief Medical Officer Dr. Hussein Sweiti, CFO Ryan Daws, Chief Legal Officer Lee Giguere, and Chief Strategy and Operations Officer Alex Nichols. Kathleen Richton will succeed Ryan Daws as principal financial officer effective July 16, 2026. enGene Therapeutics Inc. is a biotechnology company focused on developing gene therapy products.